更新于：2024-11-21

Hudan Capsule

胡丹胶囊

更新于：2024-11-21

概要

概要

基本信息

药物类型

中药

别名-

靶点-

作用机制-

治疗领域

感染消化系统疾病

在研适应症-

非在研适应症

慢性乙型肝炎

原研机构-

在研机构-

非在研机构

山东孔府制药有限公司北京世佳九生源药业科技有限公司

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

项与胡丹胶囊相关的临床试验

CTR20132225 / Completed临床2期

胡丹胶囊治疗慢性乙型肝炎（湿热蕴结证）剂量探索临床试验

为Ⅱ期临床试验提供有效、安全的临床剂量。

开始日期2008-01-01

申办/合作机构

山东孔府制药有限公司

[+1]

100 项与胡丹胶囊相关的临床结果

登录后查看更多信息

100 项与胡丹胶囊相关的转化医学

登录后查看更多信息

100 项与胡丹胶囊相关的专利（医药）

登录后查看更多信息

项与胡丹胶囊相关的文献（医药）

2008-03-01·Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials

[Effects of HuDan Granules on lipid metabolism and antioxidant activity of mice with hyperlipidemia].

Article

作者: Zheng, Meng-Wei ; Zheng, Lin

OBJECTIVETo study the effects of HuDan Granules on lipid metabolism and antioxidant activity of mice with hyperlipidemia.METHODSSeventy-eight mice were divided into six groups randomly: the normal control group, hyperlipemia group, HuDan Granules high, middle, low dose group and the Simvastatin group. Besides the normal control group, all the mice in the other groups were fed with lipid emulsion for 4 weeks. The Chinese medicine groups were treated with HuDan Granules at the dose of 12,6,3 g/kg, the normal control group and hyperlipemia group were treated with normal sodium, the Simvastatin group were treated with Simvastatin. After 4 weeks, the TC, TG, HDL-C, LDL-C, SOD, GSH-Px and LPO in serum were measured.RESULTSHuDan Granules groups could significantly decrease the serum TC, TG, HDL-C in the experimental hyperlipidemia mice, and markedly increase the level of serum HDL-C. Mean level of serum LPO in the experimental groups treated by HuDan Granules at different dosages were much lower than that in hyperlipidemia group (P<0.05), but higher than the Simvastatin group (P<0.05). And the SOD and GSH-Px activities of serum in the group of HuDan Granules were much higher than those in hyperlipidemia group and the Simvastatin group (P<0.05).CONCLUSIONHuDan Granules can regulate lipid metabolism, enhance the antioxidation and reduce the lipid peroxidation in mice with hyperlipidemia.

1998-06-01·Current Medical Science

Effects of huangdan capsule on plasma cGMP and ANP in rats with chronic renal failure

Article

作者: J Chen ; J Zheng ; C Zhang ; S Hong ; S Chen

The model of chronic renal failure (CRF) was made in 5/6 nephrectomized rats and Huangdan capsule was used to treat these rats. The levels of cyclic guanosine monophosphate (cGMP) and atrial natriuretic peptide (ANP) in plasma were examined. The results showed that Huangdan capsule could postpone the increase in the levels of cGMP and ANP, suggesting that by regulating the water and sodium metabolism, Huangdan capsule could ameliorate the glomerular filtration rate, and that Huangdan capsule could lower the levels of cGMP and ANP in plasma via body regulation.

1998-02-01·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical study on effect of huancongdan capsule in treating senile vascular dementia].

Article

作者: Cheng, W ; Zhou, W ; Chen, K

OBJECTIVETo observe the effect of Huancongdan (HCD) capsule on senile vascular dementia (SVD).METHODSSeventy two cases of SVD were divided randomly into two groups. The HCD group (37 cases) were treated with HCD and the control group (35 cases) treated with Hydergine.RESULTSAfter 2 months of treatment, the clinical symptoms, hyponeural defect, self-care capability and abnormal ratio of whole blood viscosity to plasma viscosity in HCD group were significantly different as compared with before treatment (P < 0.05).CONCLUSIONThe effect of HCD for treatment of SVD was affirmative.

100 项与胡丹胶囊相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性乙型肝炎	临床2期	中国	北京世佳九生源药业科技有限公司	2008-01-01
慢性乙型肝炎	临床2期	中国	山东孔府制药有限公司	2008-01-01